SUNNYVALE, Calif. (AP) -- Diagnostics maker Cepheid said Tuesday it will work with Oregon Health & Science University to develop tests that predict the risk of recurrence of breast and prostate cancer.
Cepheid said it will work with OHSU's Knight Cancer Institute. The tests will run on the Cepheid GeneXpert system. The company said it plans to call the breast cancer test the Xpert Breast Cancer Signature, and said the test will be designed to predict the risk of recurrence in newly diagnosed patients. The Xpert Prostate Cancer Recurrence Risk test will be designed to predict the risk of recurrence after surgery.
Shares of Cepheid rose 22 cents to $35.40 on Tuesday. The stock was unchanged in late trading.
- Disease & Medical Conditions
- prostate cancer